查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1347373

HIV 药物市场：2023-2028 年全球行业趋势、份额、规模、增长、机会和预测

HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

市场概况：

2022年全球艾滋病药物市场规模达到305亿美元。展望未来，IMARC集团预计到2028年市场规模将达到388亿美元，2023-2028年復合年增长率（CAGR）为3.95%。

人类免疫缺乏病毒（HIV）是一种慢性且危及生命的疾病，可以通过血液和性接触从一个人传播到另一个人。它是一种攻击称为 CD-4 细胞的免疫细胞的病毒，使身体容易受到感染和其他疾病。多年来，全球艾滋病毒患病率不断上升，对艾滋病毒药物的需求产生了积极影响。艾滋病毒药物有助于防止艾滋病毒的繁殖，从而降低其传播风险。

促进全球艾滋病毒药物市场增长的主要因素之一是艾滋病毒患病率及其诊断的增加。除此之外，市场还受到政府为提高人们对病因、症状和治疗认识而采取的倡议数量增加的影响。此外，仿製药的引入具有成本效益且化学成分与品牌药相同，这是增加艾滋病毒药物需求的另一个因素。

本报告回答的关键问题

  • 2022年全球艾滋病毒药物市场规模有多大？
  • 2023-2028年全球艾滋病药物市场的预期增长率是多少？
  • COVID-19 对全球 HIV 药物市场有何影响？
  • 推动全球艾滋病药物市场的关键因素是什么？
  • 根据药物类别，全球艾滋病毒药物市场的细分情况如何？
  • 全球艾滋病毒药物市场的分销渠道划分如何？
  • 全球艾滋病药物市场的关键区域有哪些？
  • 全球艾滋病药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围和方法

  • 研究目的
  • 利益相关者
  • 数据源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球 HIV 药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 价格分析
  • 按药物类别分類的市场细分
  • 按分销渠道分類的市场细分
  • 按地区分類的市场细分
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
    • 概述
    • 研究与开发
    • 原材料采购
    • 製造业
    • 行销
    • 分配
    • 最终用途
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁

第 6 章：按药物类别分類的市场细分

  • 核苷逆转录酶抑製剂
    • 市场走向
    • 市场预测
  • 多类别组合产品
    • 市场走向
    • 市场预测
  • 蛋白酶抑製剂
    • 市场走向
    • 市场预测
  • HIV 整合酶链转移抑製剂
    • 市场走向
    • 市场预测
  • 非核苷逆转录酶抑製剂
    • 市场走向
    • 市场预测
  • 进入抑製剂 - CCR5 共受体拮抗剂
    • 市场走向
    • 市场预测
  • 融合抑製剂及其他
    • 市场走向
    • 市场预测

第 7 章：按分销渠道分類的市场细分

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药店
    • 市场走向
    • 市场预测
  • 网上药店
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：按地区分類的市场细分

  • 北美
    • 市场走向
    • 市场预测
  • 欧洲
    • 市场走向
    • 市场预测
  • 亚太地区
    • 市场走向
    • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场预测
  • 拉美
    • 市场走向
    • 市场预测

第 9 章：HIV 药物生产流程

  • 产品概述
  • 原材料要求
  • 製造流程
  • 关键成功因素和风险因素

第 10 章：竞争格局

  • 市场结构
  • 关键参与者的市场细分
  • 关键参与者简介
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • Daiichi Sankyo
    • Emcure
    • Hetero Drugs
    • Mylan
Product Code: SR112023A953

Market Overview:

The global HIV drugs market size reached US$ 30.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 38.8 Billion by 2028, exhibiting a growth rate (CAGR) of 3.95% during 2023-2028.

Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.

This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Key Questions Answered in This Report

  • 1. What was the size of the global HIV drugs market in 2022?
  • 2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
  • 3. What has been the impact of COVID-19 on the global HIV drugs market?
  • 4. What are the key factors driving the global HIV drugs market?
  • 5. What is the breakup of the global HIV drugs market based on the drug class?
  • 6. What is the breakup of the global HIV drugs market based on the distribution channel?
  • 7. What are the key regions in the global HIV drugs market?
  • 8. Who are the key players/companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global HIV Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Price Analysis
  • 5.5 Market Breakup by Drug Class
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Overview
    • 5.10.2 Research and Development
    • 5.10.3 Raw Material Procurement
    • 5.10.4 Manufacturing
    • 5.10.5 Marketing
    • 5.10.6 Distribution
    • 5.10.7 End-Use
  • 5.11 Porters Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

  • 6.1 Nucleoside Reverse Transcriptase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Multi-Class Combination Products
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protease Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 HIV Integrase Strand Transfer Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Fusion Inhibitors and Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Boehringer Ingelheim International GmbH
    • 10.3.2 Merck & Co., Inc.
    • 10.3.3 ViiV Healthcare
    • 10.3.4 AbbVie
    • 10.3.5 F. Hoffmann-La Roche Ltd.
    • 10.3.6 Teva Pharmaceutical Industries Ltd.
    • 10.3.7 Bristol-Myers Squibb
    • 10.3.8 Gilead Sciences, Inc.
    • 10.3.9 Johnson & Johnson
    • 10.3.10 Cipla Limited
    • 10.3.11 Daiichi Sankyo
    • 10.3.12 Emcure
    • 10.3.13 Hetero Drugs
    • 10.3.14 Mylan

List of Figures

  • Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2022
  • Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: HIV Drugs Industry: SWOT Analysis
  • Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
  • Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
  • Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2017 & 2022
  • Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2023-2028
  • Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2017 & 2022
  • Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2023-2028
  • Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2017 & 2022
  • Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2023-2028
  • Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2017 & 2022
  • Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2023-2028
  • Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
  • Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

  • Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: HIV Drugs Manufacturing: Raw Material Requirements
  • Table 6: Global: HIV Drugs Market: Competitive Structure
  • Table 7: Global: HIV Drugs Market: Key Players